Baxter pays $157 million for haemostat company Fusion
This article was originally published in Clinica
Executive Summary
Baxter is to expand its biosurgery and tissue repair business by buying Fusion Medical Technologies in a $157 million stock-for-stock merger. Baxter is offering $10 per share, representing a 20% premium on Fusion's share price before the announcement of the deal. It subsequently rose 18% to $9.80.